Cost-Sharing and Utilization of Biologic and Non-Biologic Dmards Among US Medicare Beneficiaries with Rheumatoid Arthritis.

被引：0
|
作者：
Tonner, Chris [1 ]
Schmajuk, Gabriela [1 ]
Yazdany, Jinoos [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2464
引用
收藏
页码：S1038 / S1038
页数：1
相关论文
共 50 条
  • [1] Prevalence of Biologic Utilization Over Calendar Time Among Medicare Beneficiaries with Rheumatoid Arthritis.
    Zhang, Jie
    Xie, Fenglong
    Delzell, Elizabeth S.
    Chen, Lang
    Lewis, James
    Haynes, Kevin
    Saag, Kenneth G.
    Curtis, Jeffrey
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S163 - S163
  • [2] COST-SHARING AND USE OF BIOLOGIC THERAPIES IN MEDICARE PATIENTS WITH RHEUMATOID ARTHRITIS
    Doshi, J. A.
    Li, P.
    Hu, T.
    Subedi, P.
    Davis-Cerone, M.
    VALUE IN HEALTH, 2014, 17 (03) : A54 - A54
  • [3] RISK OF VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC AND NON-BIOLOGIC DMARDS
    Maro, J. C.
    Menzin, T.
    Hornbuckle, K.
    Giles, J. T.
    Kavanaugh, A.
    Doerner, T.
    Martin, D.
    Huang, T.
    Salinas, C. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 932 - 932
  • [4] Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
    Maro, Judith
    Menzin, Talia
    Hornbuckle, Kenneth
    Giles, Jon T.
    Kavanaugh, Arthur
    Doerner, Thomas
    Martin, David
    Huang, Jane
    Salinas, Claudia A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] Triple therapy with non-biologic DMARDs for rheumatoid arthritis or biologic therapy. Is it the same?
    Abud-Mendoza, Carlos
    Martinez-Martinez, Marco U.
    REUMATOLOGIA CLINICA, 2014, 10 (05): : 345 - 346
  • [6] Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
    Park, Sang Hee
    Schwartz, Taylor
    Han, Xue
    Robinson, Scott
    Kakehi, Sumie
    Wittstock, Keith
    Norris, Kris
    Murunga, Anne
    Silverstein, Alison
    Sparks, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 957 - 958
  • [7] Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards
    Ozen, Gulsen
    Pedro, Sofia
    England, Bryant R.
    Mehta, Bella
    Wolfe, Frederick
    Michaud, Kaleb
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [8] Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
    Yazdany, Jinoos
    Dudley, R. Adams
    Chen, Randi
    Tseng, Chien-Wen
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S426 - S426
  • [9] BIOLOGIC AND DMARD COMBINATION AND MONOTHERAPY AMONG MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS
    Curtis, J. R.
    Zhang, J.
    Xie, F.
    Delzell, E. S.
    Chen, L.
    Kilgore, M.
    Yun, H.
    Saag, K. G.
    Lewis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 554 - 554
  • [10] Impact of Medicare Part D on Access to and Cost Sharing for Specialty Biologic Medications for Beneficiaries With Rheumatoid Arthritis
    Polinski, Jennifer M.
    Mohr, Penny E.
    Johnson, Lorraine
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (06): : 745 - 754
12345